TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00756106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Temozolomide is administered according to standard of care practice guidelines. Dosing may be modified at the discretion of the treating investigator.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging biomarker analysis
Description: MRI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon Radiation Therapy
Description: Radiation is administered to the tumor plus edema with a 1-2 centimeter margin for a total dose of 60 Gy in 30 fractions.
Study: NCT00647179

Intervention type: PROCEDURE
Intervention: Transsphenoidal adenomectomy
Description: Surgery
Study: NCT01052792

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Sodium
Description: Naproxen Sodium Tablets 550 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium
Description: Naproxen Sodium Tablets 550 mg
Study: NCT03496259

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: On-Q pump
Description: Type of pain control device used

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural catheter
Description: Type of pain control device used
Study: NCT00930696

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extensive abdominal lavage
Description: Extensive lavage of the abdomen with 8 liters of saline at the end of the surgical procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rinsing of the abdomen
Description: Standard rinsing of the abdomen with some 0,5 liters of saline at the end of the surgical procedure
Study: NCT03045367

Intervention type: PROCEDURE
Intervention: Phacoemulsification, intraocular lens implant, vitrectomy.
Description: Cataract extraction, intraocular lens implant, vitrectomy, epiretinal membrane and inner limiting retinal membrane peeling.
Study: NCT04101630

Intervention type: BEHAVIORAL
Intervention: Activity Monitoring
Description: Monitoring with FitBit

Intervention type: BEHAVIORAL
Intervention: Activity Monitoring
Description: Monitoring with FitBit
Study: NCT03201796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg
Description: Oral administration of one tablet once daily for 28 days of prulifloxacin 600 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin 500mg
Description: Oral administration of one tablet once daily for 28 days of levofloxacin 500 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.
Study: NCT04102397

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vojta therapy after standard therapy
Description: Vojta Therapy \~20 minutes/session: Application of the Reflex Creeping complex, activating several stimulus points on the facial and the nuchal sides (Figure 3a), and then the activation of the Reflex Rolling complex in both the supine position and with the patient lying on his or her side, alternating between nuchal and facial stimulation and guiding from the head.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: \~50 minutes/session:~* TENS Current (20 minutes, phase duration=0.10 microseconds, frequency=50 Hz). The intensity applied depended on the patient's tolerance for the treatment (Figure 2a).~* Pulsating ultrasound (5 minutes around the shoulder, frequency=1MHz, intensity=1 W/cm2) (Figure 2b).~* Kinesiotherapy. In stages: at first assisted (with isometric exercises), then free, and finally, with resistance, usually with elastic bands (Figure 2c).~* Cryotherapy (5 minutes).
Study: NCT04103879

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ECT-001-CB (UM171-Expanded Cord Blood Transplant)
Description: Conditioning: High dose TBI (1320 cGy TBI + Fludarabine 75 mg/m2 + Cyclophosphamide 120 mg/kg) or Intermediate Intensity regimen (400 cGy TBI + Fludarabine 150 mg/m2 + Cyclophosphamide 50 mg/kg + Thiotepa 10 mg/kg).~Single UM171-Expanded CB transplant (CD34+: 2.5-50x10E5/kg, CD3+\>1x10E6/kg)~Immunosuppression: Tacrolimus/MMF
Study: NCT03273426

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally-invasive biopsy
Description: Intervention (core needle biopsy (14G) or vacuum-assisted biopsy(10G)) for complete clinical response (cCR) or near-cCR predicted by MRI.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally-invasive biopsy
Description: Intervention (core needle biopsy (14G) or vacuum-assisted biopsy(10G)) for complete clinical response (cCR) or near-cCR predicted by MRI.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wide excision
Description: Surgical wide excision of the biopsied area.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wide excision
Description: Surgical wide excision of the biopsied area.
Study: NCT03297957

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hands-free goggle system
Description: -Manufactured at Washington University
Study: NCT02577172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: The intervention will be conducted during chemotherapy and tailored for each patient. The program will include 1) weight bearing aerobic exercises to maintain the oxygen transport and thereby reduce the decline in VO2max during chemotherapy and 2) strength training exercises to maintain muscle mass and muscle strength. The intervention will last for 9 or 12 weeks, depending on the number of BEP/EP cycles received. The program will consist of two-three one-hour exercise sessions per week, of which most supervised by a personal trainer. The intensity of each exercise sessions will varies from easy (warm-up: 60-70 % of peak heart rate) to moderate/high (between aerobic intervals 60-70% of peak heart rate and during aerobic intervals 85-95 %).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group will receive one individual lifestyle counseling session during the first chemotherapy cycle and can perform all activities that they have planned to do during chemotherapy.
Study: NCT04443244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A Injection (Botulax®) 24Units
Description: Experimental: Botulax® 24Units

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A Injection (Botulax®) 48Units
Description: Experimental: Botulax® 48Units

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A Injection (Botulax®) 72Units
Description: Experimental: Botulax® 72Units

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A Injection (Botulax®) 96Units
Description: Experimental: Botulax® 96Units

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Placebo Comparator: Normal Saline
Study: NCT03017963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate Pentahydrate
Description: Sodium Thiosulfate Pentahydrate is administered intravenously in 250 centiliters infusion fluid in two doses: first dose with an infusion rate of 16.66 milliliter (ml) per minute (min), second dose with 8.33 ml / min
Study: NCT04420377

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carnipure
Description: Supplement contains L-carnitine tartrate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: 5 weeks of whole-body resistance training, performed 2 times per week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Training
Description: 5 weeks of whole-body resistance training, performed 2 times per week.
Study: NCT02733263

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 15 g RMD
Description: 15 grams of resistant maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 15 g RMD
Description: 15 grams of resistant maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 15 g RMD
Description: 15 grams of resistant maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 15 g RMD
Description: 15 grams of resistant maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 15 g RMD
Description: 15 grams of resistant maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 15 g RMD
Description: 15 grams of resistant maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 25 g RMD
Description: 25 grams of resistant maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 25 g RMD
Description: 25 grams of resistant maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 25 g RMD
Description: 25 grams of resistant maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 25 g RMD
Description: 25 grams of resistant maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 25 g RMD
Description: 25 grams of resistant maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 25 g RMD
Description: 25 grams of resistant maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 0 g RMD
Description: 0 grams of resistant maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 0 g RMD
Description: 0 grams of resistant maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 0 g RMD
Description: 0 grams of resistant maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 0 g RMD
Description: 0 grams of resistant maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 0 g RMD
Description: 0 grams of resistant maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 0 g RMD
Description: 0 grams of resistant maltodextrin
Study: NCT02051764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: 370 megabecquerel (MBq) IV single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetapir F 18
Description: 370 megabecquerel (MBq) IV single-dose

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain PET Scan
Description: positron emission tomography (PET) scan of the brain
Study: NCT02395458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential therapy
Description: Patient receive Omeprazole plus amoxicillin during 5 days and then omeprazole plus clarithromycin and metronidazole during another 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triple therapy
Description: Patient receive Omeprazole plus amoxicillin and Clarithromycin during 14 days
Study: NCT04207034

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: flap surgery with diode laser
Description: Patient will be asked to rinse with 0.2% chlorhexidine mouthwash. Following the administration of local anaesthesia 2% lignocaine hydrochloride ( with 1: 80,000 epinephrine) , Laser application will be carried out , with the help of 810 nm (A.R.C LASER FoxTM) diode laser with a flexible optic tip of 300µm . The sulci will be lased with a repeated beam ( 0.2 sec on 0.3 sec off) at an output power of 1.0 W.~Intracrevicular incision will be placed with the help of 15c Bard Parker surgical blade , full thickness mucoperiosteal flap will be elevated .~Debridement of granulation tissue will be done and flap will be suture back in position using 3-0 black breaded silk suture, the site will be covered with non eugenol periodontal dressing for protection.~Postoperative instructions will be given to the patient. 2 ml blood will be collected at baseline(sample 1) , at 5 minutes (sample 2) and within 20-30 minutes (sample 3) of starting the procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: flap surgery
Description: Patient will be asked to rinse with 0.2% chlorhexidine mouthwash. Following the administration of local anaesthesia 2% lignocaine hydrochloride ( with 1:80,000 epinephrine) ,intracrevicular incision will be placed with the help of 15c Bard Parker surgical blade , full thickness mucoperiosteal flap will be elevated .~Debridement of granulation tissue will be done and flap will be suture back in position using 3-0 black breaded silk suture, the site will be covered with non eugenol periodontal dressing for protection.~Postoperative instructions will be given to the patient. 2 ml blood will be collected at baseline(sample 1) , at 5 minutes (sample 2) and within 20-30 minutes (sample 3) of starting the procedure
Study: NCT03173885

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Preimplantation Genetic Screening
Description: * laser assisted hatching~* trophectoderm biopsy~* next generation sequencing
Study: NCT04228471

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spontaneous breathing activity during APRV
Description: Allowing spontaneous breathing activity with APRV throughout the first 48 hours.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No spontaneous breathing activity
Description: No spontaneous breathing activity will be allowed with pressure controlled ventilation throughout the first 48 hours.
Study: NCT01468558

Intervention type: DRUG
Group type: OTHER
Intervention: MAP0004
Description: MAP0004 1.0mg via inhalation on Day 1 and Day 6 of Visit 2

Intervention type: DRUG
Group type: OTHER
Intervention: IV DHE
Description: IV DHE (Intravenous Dihydroergotamine Mesylate) administered at Visit 3

Intervention type: DRUG
Group type: OTHER
Intervention: Ketoconazole
Description: Ketoconazole 400 mg administered once a day on days 3-6 of Visit 2
Study: NCT02249338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01260649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: eligible patients will be randomly assigned to a double-blind administration of ketamine (0.5 mg/kg) or IV Saline, followed by the routine anesthetic agent and muscle relaxant. ECT will be administered as per standard of care

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IV Saline
Description: eligible patients will be randomly assigned to a double-blind administration of ketamine (0.5 mg/kg) or IV Saline, followed by the routine anesthetic agent and muscle relaxant. ECT will be administered as per standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECT
Description: ECT will be administered as per standard of care

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ECT
Description: ECT will be administered as per standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Muscle Relaxant
Description: All participant will receive routine course of muscle relaxant with ECT as per standard of care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Muscle Relaxant
Description: All participant will receive routine course of muscle relaxant with ECT as per standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthetic Agents
Description: All participant will receive routine course of anesthetic agents with ECT as per standard of care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anesthetic Agents
Description: All participant will receive routine course of anesthetic agents with ECT as per standard of care
Study: NCT00623948

Intervention type: DEVICE
Group type: OTHER
Intervention: A fully implanted gluteal stimulation (GSTIM) system
Description: A fully implanted gluteal stimulation system
Study: NCT02343263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 1 milliliter (mL) of 0.75% Bupivacaine Hydrochloride will be infused into 4mL of fibrin sealant (diluting the Bupivacaine HCl to 0.15%). The bupivacaine-infused fibrin sealant will then be applied to the tonsillectomy (or adenotonsillectomy) wound bed.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fibrin Sealant
Description: Fibrin sealant will be applied to the wound bed topically as per product instructions.
Study: NCT01605006

Intervention type: DEVICE
Group type: OTHER
Intervention: NeuRx Diaphragm Pacing System (DPS)
Description: The NeuRx DPS is a percutaneous, intramuscular, diaphragm stimulation system which is implanted using standard laparoscopic surgical techniques in an outpatient procedure. The implanted intramuscular diaphragm electrodes are connected to a four channel external stimulator at a percutaneous exit site. DPS is designed to help ALS patients breathe by providing conditioning stimulation of the diaphragm muscles. Recommended frequency of diaphragm conditioning is at least 3 times per day with each session lasting at least 30 minutes. Patients may find it helpful to use the DPS for longer periods to help with breathing. DPS may be used at the same time as non-invasive ventilation. Patents may also sleep with the DPS to assist with breathing difficulties at night.
Study: NCT00988832

Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: Infliximab as prescribed by a physician in normal practice for Crohn's disease
Study: NCT03521349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Egg Intervention
Description: Participants will consume an isocaloric muffin containing important bioactives from whole eggs.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Egg White Control
Description: Participants will consume an isocaloric muffin containing egg white, lacking important bioactives from whole eggs.
Study: NCT02404961

Intervention type: OTHER
Intervention: Vulvodynia
Description: Comparison of reproductive, gynecological and environmental exposures, psychological trauma and psychiatric morbidity, and biological markers of immuno-inflammation and nerve fiber proliferation between cases and controls to determine potential etiology of vulvodynia.

Intervention type: OTHER
Intervention: Vulvodynia
Description: Comparison of reproductive, gynecological and environmental exposures, psychological trauma and psychiatric morbidity, and biological markers of immuno-inflammation and nerve fiber proliferation between cases and controls to determine potential etiology of vulvodynia.
Study: NCT04468646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK-1R antagonist
Description: NK-1R antagonist, 80 mg daily once for 3-5 days along with dexamethasone 6 mg daily for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NK-1R antagonist
Description: NK-1R antagonist, 80 mg daily once for 3-5 days along with dexamethasone 6 mg daily for 5 days
Study: NCT06079008

Intervention type: OTHER
Intervention: calcified cardiac valve
Description: patients have cardiac cardiac valve before surgery

Intervention type: OTHER
Intervention: calcified cardiac valve
Description: patients have cardiac cardiac valve before surgery
Study: NCT02329444

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: Appropriately sized sphygmomanometer cuff placed around right upper arm; where contraindicated, left arm, with inflation of the cuff up to 200mmHg for 5 minutes, followed by deflation of 5 minutes to allow reperfusion with cycle repeated 3 times.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham ischemic preconditioning
Description: Appropriately sized sphygmomanometer cuff placed around right upper arm; where contraindicated, left arm, with inflation of the cuff up to 50mmHg for 5 minutes, followed by deflation of 5 minutes to allow reperfusion with cycle repeated 3 times.
Study: NCT04917172

Intervention type: DIAGNOSTIC_TEST
Intervention: postoperative acute pancreatitis evaluation
Description: Surgical resection and reconstruction will be carried out according to the Institutional standards. After the surgical procedure, serum pancreatic amylase and lipase activity will be systematically measured two hours after surgery on postoperative day (POD) 0 and every day at 7 a.m. until POD 5 according to our institutional policy. At our institution, the upper limit of normal for serum pancreatic amylase is 52 U/L and for serum lipase is 60 U/L. Postoperative protocols included the routine measurement of inflammatory markers (white blood cell \[WBC\] count and C-Reactive Protein \[CRP\]). A urine trypsinogen strip test will be done on POD 1. A trypsinogen-2 concentration of more than 50 µg/l is considered a positive test. As routine clinical practice, a post-operative imaging will be scheduled to check for potential surgical morbidity. Abdominal magnetic resonance imaging (MRI) will be assessed on POD 3.
Study: NCT03593902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: A chemotherapy medication commonly used in the treatment of leukemia and lymphoma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: A medication used as chemotherapy and to suppress the immune system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rATG
Description: A rabbit polyclonal antibody to lymphocytes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: A corticosteroid medication used to suppress the immune system and decrease inflammation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVIg
Description: Pooled immunoglobulin (IgG) from thousands of plasma donors that has immunomodulatory and anti-inflammatory effects

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cells
Description: Infusion of patient's own stem cells
Study: NCT03922100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMS-03592088
Description: Route of administration: Oral
Study: NCT02666872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Study: NCT00464698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Participants received increasing amounts of Duloxetine for 7 weeks.